Von Eschenbach takes leave of absence from NCI, resigns from C-Change board. Acting FDA commissioner’s drug approval strategy rooted in unproven science. Von Eschenbach told NCI deputies he might drop in on meetings. Who’s really in charge?
John Niederhuber named NCI chief operating officer; the surgeon was asked to leave two previous positions.
Cancer death rate dropping 1.1 percent a year, annual report finds.
Trending Stories
- Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives - From “default dead” to living the future of cancer care
As founding CEO of GitLab, I went “founder mode” on my osteosarcoma - The end of “more money, more people, more trials”
Cancer centers are being asked to grow their portfolios on flat budgets. Headcount is the wrong answer. - Harold Freeman, a surgeon who championed health equity, dies at 93
Freeman, the father of patient navigation, served as president of ACS and chair of the President’s Cancer Panel - Letai takes a swipe at “ill-informed commentators,” as he lays out his scientific vision for NCI
“To my knowledge, 100% of grants that clear my desk get funded” - Senthil K. Muthuswamy named director of NCI’s Center for Cancer Research
